VSee Health (VSEE) grants 40,107 common shares to director

Rhea-AI Filing Summary

VSEE HEALTH, INC. director Kevin Lowdermilk acquired 40,107 shares of common stock at a price of $0.374 per share. These shares were issued under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025, based on the stock’s closing price that day. Following this grant, he directly holds 108,731 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOWDERMILK KEVIN

(Last) (First) (Middle)

C/O VSEE HEALTH, INC.

980 N FEDERAL HWY #304

(Street)

BOCA RATON FL 33432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VSEE HEALTH, INC. [ VSEE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	03/04/2026		A		40,107	A	$0.374(1)	108,731	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended December 31, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on December 31, 2025.

	/s/ Kevin Lowdermilk	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VSEE director Kevin Lowdermilk report on this Form 4?

Kevin Lowdermilk reported receiving 40,107 shares of VSee Health common stock. The shares were issued as equity compensation for his service as a non-employee director for the quarter ended December 31, 2025, under the company’s 2024 Incentive Plan.

At what price were the 40,107 VSEE common shares granted to Kevin Lowdermilk?

The 40,107 common shares were valued at $0.374 per share. The number of shares issued to Kevin Lowdermilk was calculated using the closing price of VSee Health’s common stock on December 31, 2025, under the 2024 Incentive Plan’s terms.

How many VSEE shares does Kevin Lowdermilk own after this reported grant?

After this equity grant, Kevin Lowdermilk directly owns 108,731 shares of VSee Health common stock. This total reflects the addition of 40,107 shares issued as compensation for his service as a non-employee director in the quarter ended December 31, 2025.

What is the source of the 40,107 VSEE shares granted to Kevin Lowdermilk?

The 40,107 shares were issued under VSee Health’s 2024 Incentive Plan. They were granted in accordance with the company’s non-employee director compensation policy for services as a director during the quarter ended December 31, 2025, using the closing stock price that day.

Does the Form 4 indicate that Kevin Lowdermilk bought or was granted VSEE shares?

The Form 4 indicates that Kevin Lowdermilk was granted, not bought, 40,107 VSee Health common shares. The transaction is coded as a grant, award, or other acquisition under the 2024 Incentive Plan for his non-employee director service compensation.